Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Hero

Showing results (41-50 of 141) with videos related to

Pageof 15
Sort By:
Cancer Medicine|October 22, 2019
A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosisKiana Kreitz, Angela Ernst, René Schmidt, et al.
Developmental Medicine and Child Neurology|February 15, 2012
Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastomaThorsten Simon, Catherina Annika Niemann, Barbara Hero, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 4, 2014
Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practiceHeike Hoyer-Kuhn, Sina Kohbrok, Ruth Volland, et al.
Cancer Research|October 19, 2006
Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastomaSimone Fulda, Christopher Poremba, Bernd Berwanger, et al.
JNCI Cancer Spectrum|July 9, 2021
Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled TrialFrank Berthold, Claudia Spix, Rudolf Erttmann, et al.
Journal of Cancer Research and Clinical Oncology|May 5, 2007
Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trialThorsten Simon, Alfred Längler, Urs Harnischmacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPARAndré Oberthuer, Lars Kaderali, Yvonne Kahlert, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2005
Low occurrence of familial neuroblastomas and ganglioneuromas in five consecutive GPOH neuroblastoma treatment studiesAlexander Claviez, Max Lakomek, Jörg Ritter, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|April 23, 2003
Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastomaHans Theodor Eich, Barbara Hero, Susanne Staar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison studyBoris Decarolis, Christina Schneider, Barbara Hero, et al.
Pageof 15

Showing results (41-50 of 141) with videos related to

Sort By:
Pageof 15
Cancer Medicine|October 22, 2019
A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosisKiana Kreitz, Angela Ernst, René Schmidt, et al.
Developmental Medicine and Child Neurology|February 15, 2012
Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastomaThorsten Simon, Catherina Annika Niemann, Barbara Hero, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 4, 2014
Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practiceHeike Hoyer-Kuhn, Sina Kohbrok, Ruth Volland, et al.
Cancer Research|October 19, 2006
Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastomaSimone Fulda, Christopher Poremba, Bernd Berwanger, et al.
JNCI Cancer Spectrum|July 9, 2021
Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled TrialFrank Berthold, Claudia Spix, Rudolf Erttmann, et al.
Journal of Cancer Research and Clinical Oncology|May 5, 2007
Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trialThorsten Simon, Alfred Längler, Urs Harnischmacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPARAndré Oberthuer, Lars Kaderali, Yvonne Kahlert, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2005
Low occurrence of familial neuroblastomas and ganglioneuromas in five consecutive GPOH neuroblastoma treatment studiesAlexander Claviez, Max Lakomek, Jörg Ritter, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|April 23, 2003
Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastomaHans Theodor Eich, Barbara Hero, Susanne Staar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison studyBoris Decarolis, Christina Schneider, Barbara Hero, et al.
Pageof 15